Clinical Trial Update: Osimertinib for Advanced EGFR-positive NSCLC Patients

View source ↗

Summary

A clinical trial is evaluating Osimertinib for advanced EGFR-positive non-small cell lung cancer and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: EGFR Positive Non-small Cell Lung Cancer, Non Small Cell Lung Cancer | Status: RECRUITING